VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Women With CF Use Combined Hormonal Contraceptives More Than Other Methods, Study Reports

CHMP Gives Positive Opinion to Vertex’s Triple Combination Therapy Kaftrio

Kalydeco Approved in Europe to Treat Children with R117H Mutation

Real-world Use of Kalydeco for CF Highly Effective, Large-scale Analysis Shows

This new treatment helps 90% of cystic fibrosis patients breathe better

UK NICE to Announce Decision on Vertex’s Therapy Trikafta in December

Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand